With oral anticoagulant Xarelto
(rivaroxaban) set to be listed
on the Pharmaceutical Benefits
Scheme for preventing stroke, NPS
MedicineWise is urging people to
talk to their doctor before stopping
or making any changes to their
anticoagulant medicines.
Xarelto will be subsidised from
tomorrow for preventing stroke
in people with atrial fibrillation, a
heart condition which increases
the risk of harmful blood clots that
cause stroke.
It will also be subsidised for
treating pulmonary embolism - a
blood clot in the lung.
Xarelto is the one of the new
range of anticoagulants challenging
the dominant role of warfarin with
simpler dosing and no need for INR
blood tests.The above article was sent to subscribers in Pharmacy Daily's issue from 31 Jul 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 31 Jul 13
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.